![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
TJ Abbruscato, SA Williams, A Misicka, AW Lipkowski, VJ Hruby and TP Davis
Department of Pharmacology, University of Arizona, College of Medicine, Tucson, USA.
Biphalin (Tyr-D-Ala-Gly-Phe-NH)2 is a unique opioid peptide analog that contains two active enkephalin pharmacophores and is more potent than morphine and etorphine in eliciting analgesia after intrathecal administration. After systemic administration, only a small amount was detected in the brain, but analgesia was observed. Because halogenation of enkephalin analogs has been shown to increase the brain uptake after systemic administration, our research group synthesized both p-[Cl- Phe4,4']biphalin and p-[F-Phe4,4']biphalin. The aim of the present study was to characterize and compare the blood-to-central nervous system (CNS) pharmacokinetics and biological stability of biphalin and related halogenated analogs. The initial screening used an in vitro blood-brain barrier model and identified p-[Cl-Phe4,4')biphalin as the enkephalin analog with the best potential for greater CNS entry. The CNS uptake and stability of biphalin and p-[Cl-Phe4,4']biphalin was examined further using an in situ brain perfusion technique coupled to high-performance liquid chromatography analysis. Both biphalin and its chlorohalogenated analog, were found to significantly enter the CNS through both the blood-brain and blood-cerebrospinal fluid barriers. Chlorohalogenation of biphalin was shown to both improve CNS entry, most likely through an enhancement in lipophilicity, and increase biological stability. This study suggests that incorporation of chlorohalogens at the p-Phe4,4' position is a promising structural modification in the development of biphalin as a successful opioid drug for the clinic.
This article has been cited by other articles:
|
|
 |
|
  H.-M. Liu, X.-F. Liu, J.-L. Yao, C.-L. Wang, Y. Yu, and R. Wang Utilization of Combined Chemical Modifications to Enhance the Blood-Brain Barrier Permeability and Pharmacological Activity of Endomorphin-1 J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 308 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Witt, J. D. Huber, R. D. Egleton, and T. P. Davis Pluronic P85 Block Copolymer Enhances Opioid Peptide Analgesia J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 760 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Witt, J. D. Huber, R. D. Egleton, M. J. Roberts, M. D. Bentley, L. Guo, H. Wei, H. I. Yamamura, and T. P. Davis Pharmacodynamic and Pharmacokinetic Characterization of Poly(Ethylene glycol) Conjugation to Met-Enkephalin Analog [D-Pen2,D-Pen5]-enkephalin (DPDPE) J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 848 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Abbruscato and T. P. Davis Combination of Hypoxia/Aglycemia Compromises In Vitro Blood-Brain Barrier Integrity J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 668 - 675. [Abstract] [Full Text]
|
|
|
|
|
|
S. A. Thomas, T. J. Abbruscato, V. J. Hruby, and T. P. Davis The Entry of [D-Penicillamine2,5]Enkephalin into the Central Nervous System: Saturation Kinetics and Specificity J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1235 - 1240. [Abstract] [Full Text]
|
|
|
|
|
|
T. J. Abbruscato, S. A. Thomas, V. J. Hruby, and T. P. Davis Blood-Brain Barrier Permeability and Bioavailability of a Highly Potent and µ-Selective Opioid Receptor Antagonist, CTAP: Comparison with Morphine J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 402 - 409. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
